Morgan Stanley says Hims branded tirzepatide margins likely well below compounds

After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded tirzepatide and generic liraglutide, Morgan Stanley analyst Craig Hettenbach said an expanding offering could help ease some concerns over the company’s target of $725M in weight loss revenue in 2025. However, margins that Hims realizes for branded tirzepatide are likely well below their compounded GLP-1 products, the analyst tells investors. The firm, which argues that the durability of personalized compounded GLP-1 and momentum in oral weight loss drugs remain the biggest factors in determining whether Hims will deliver on its revenue guidance, keeps an Equal Weight rating and $60 price target on Hims shares.